<DOC>
	<DOC>NCT00829049</DOC>
	<brief_summary>Comparison of the safety and efficacy of Tazarotene Cream 0.1% compared with Adapalene Gel 0.3% in treating moderate to severe facial acne vulgaris</brief_summary>
	<brief_title>Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Adapalene</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Facial acne vulgaris characterized by the following: 25100 facial inflammatory lesions (papules plus pustules); and 40 or more noninflammatory lesions (open/closed comedones)); stable disease, nonrapidly regressing facial acne vulgaris; and, 3 or less facial nodules and/or cysts (diameter of 1cm or greater). Female subjects of childbearing potential must have a negative urine pregnancy test at baseline and practice reliable method of contraception throughout the study. Noncompliance with washout period Skin disease/disorder that might interfere with diagnosis or evaluation of acne vulgaris Allergy or sensitivity to any component of the test medications Cosmetic or surgical procedure complementary to the treatment of facial acne within 14 days of the baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>